From: Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
 | Baseline (n = 114) | End of Treatment (n = 112) | Difference (n = 112) |
---|---|---|---|
UPDRS | Â | Â | Â |
   I | 1.9 ± 1.8 | 1.4 ± 1.6 | -0.5 ± 1.2 |
   II | 7.8 ± 5.3 | 6.9 ± 4.9 | -0.9 ± 3.3 |
   III | 17.9 ± 10.3 | 15.9 ± 10.0 | -1.9 ± 5.9 |
   IV | 2.7 ± 3.1 | 2.2 ± 2.8 | -0.4 ± 1.8 |
 | Baseline (n = 114) | End of Treatment (n = 111) | Difference (n = 111) |
NMSS | Â | Â | Â |
   Total | 29.5 ± 30.5 | 21.8 ± 22.2 | -7.9 ± 19.8 |
   Cardiovascular | 0.8 ± 1.3 | 0.7 ± 2.6 | -0.0 ± 2.7 |
   Sleep/fatigue | 5.8 ± 7.3 | 4.8 ± 6.0 | -0.9 ± 6.7 |
   Mood/cognition | 4.6 ± 9.1 | 2.7 ± 6.6 | -1.9 ± 6.2 |
   Perceptual problems | 0.2 ± 1.3 | 0.1 ± 0.7 | -0.1 ± 1.1 |
   Attention/memory | 3.4 ± 4.7 | 2.4 ± 4.1 | -1.0 ± 3.7 |
   Gastrointestinal | 2.3 ± 4.0 | 1.7 ± 3.0 | -0.6 ± 3.6 |
   Urinary | 6.3 ± 9.9 | 5.2 ± 7.6 | -1.3 ± 5.3 |
   Sexual dysfunction | 1.3 ± 3.5 | 0.9 ± 3.2 | -0.4 ± 1.8 |
   Miscellaneous | 4.8 ± 6.4 | 3.3 ± 5.4 | -1.6 ± 5.6 |